A2 milk is cow's milk in which the beta-casein protein is entirely the A2 variant, with no A1 beta-casein present. It comes from cows that carry two copies of the A2 allele of the CSN2 gene.

A1 vs A2 Milk: What the Beta-Casein Difference Means

Name: A1 vs A2 Milk: What the Beta-Casein Difference Means
Creator: Dr. Zubair Khalid

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-27

A1 and A2 milk differ by a single amino acid in the beta-casein protein: position 67 is histidine in A1 and proline in A2. That one substitution changes how digestive enzymes cut the protein, and it is the reason A1 beta-casein can release a short opioid-like peptide called beta-casomorphin-7 (BCM-7) during digestion while A2 beta-casein generally does not [1].

Everything else about the two milks is nearly identical. Both contain lactose, both contain the same broad mix of caseins and whey proteins, and both are nutritionally complete dairy foods. The A1 versus A2 question is narrow and specific, and it has generated far more marketing heat than settled science. This article explains the biology, summarizes what randomized trials actually found, describes how dairy herds are converted to A2 genetics, and states plainly what remains unproven.

Key Takeaways

A1 and A2 milk differ by one amino acid at position 67 of beta-casein: histidine in A1 and proline in A2, which changes how digestive enzymes cut the protein.
A1 beta-casein can release beta-casomorphin-7 (BCM-7), an opioid-like peptide, during digestion, while A2 beta-casein generally does not because proline blocks enzyme cleavage at that site.
Only cows carrying two copies of the A2 allele (A2A2) produce milk free of A1 beta-casein, and herd conversion requires genotyping, breeding A1 carriers to A2A2 bulls, and generational replacement.
A2 milk contains lactose and is not lactose-free, so it is not suitable for lactose intolerance despite marketing claims.
Several randomized trials in self-reported milk-intolerant people found fewer digestive symptoms with A2 milk, but other trials found no difference, and many positive trials were funded by The a2 Milk Company.

What Is A2 Milk?

A2 milk is cow's milk in which the beta-casein fraction is made up entirely of the A2 variant, with no A1 beta-casein present [2][3]. It is not a different species, a plant milk, or a processed product. It is ordinary cow's milk selected from cows that carry two copies of the A2 allele of the CSN2 gene.

Beta-casein makes up roughly 30 percent of the protein in cow's milk [4]. The CSN2 gene that encodes it exists in several variants, and A1 and A2 are the two most common in dairy herds worldwide [5]. Because a cow inherits one CSN2 allele from each parent, an animal can be A1A1, A1A2, or A2A2. Only A2A2 cows produce milk free of A1 beta-casein. A1A2 cows produce milk with a mix, and A1A1 cows produce milk that is entirely A1 type.

Conventional milk on a US grocery shelf is a blend from many cows and typically contains both variants. The ratio varies by herd, and one trial used conventional milk with an A1 to A2 ratio of 58 to 42 [5], while another described conventional milk as roughly 75 percent A1 and 25 percent A2 [3][4]. That variability matters when you try to compare studies, because "conventional milk" is not a fixed product.

The Single Amino Acid That Started the Debate

Beta-casein is a chain of 209 amino acids. Position 67 sits in a region that digestive enzymes recognize. In A2 beta-casein, position 67 is proline. In A1 beta-casein, it is histidine [1].

Proline creates a kink in the protein backbone that makes the nearby bond resistant to cleavage by gastrointestinal proteases. Histidine does not create that kink, so the bond is exposed. When A1 beta-casein is digested, enzymes can cut at that site and release a seven-amino-acid fragment, beta-casomorphin-7 [6][1].

BCM-7 is an opioid-like peptide. It binds mu-opioid receptors, which are expressed throughout the gastrointestinal tract and elsewhere in the body [6]. This is the mechanistic heart of the A1 versus A2 hypothesis: A1 beta-casein yields a bioactive peptide during digestion, and A2 beta-casein largely does not.

Two caveats belong here. First, BCM-7 is not unique to A1. Variant B beta-casein also releases it, though A1 is far more common in commercial dairy herds [1]. Second, the amount that reaches the bloodstream is contested. One human crossover study found that consuming A2 milk did not raise plasma BCM-7 concentrations compared with a washout diet [7], and a 2025 analysis of raw and processed dairy products found BCM-7 levels were low and did not vary significantly by CSN2 genotype or processing method [8]. In vitro release of a peptide is not the same as a measurable systemic exposure in a person.

A1 Milk and A2 Cow Milk: The Genetics Behind the Label

The A1 and A2 variants are not evenly distributed across breeds. Breed differences in allele frequency are well documented and are the practical foundation of the A2 dairy industry.

Holstein-Friesian cattle, the dominant breed in US dairy production, carry A1 at high frequency. Reported A1 frequencies range from 0.310 to 0.660 in Holstein-Friesian, 0.432 to 0.720 in Ayrshire, and around 0.710 in Red cattle [1]. A1 is described as prevalent in Holstein-Friesian herds [8].

Guernsey and Jersey cattle sit at the other end. Reported A2 frequencies are 0.880 to 0.970 in Guernsey and 0.490 to 0.721 in Jersey [1]. Jersey milk appears in A2 research partly for this reason, and one crossover trial included Jersey milk as one of four test milks [9].

The picture is not perfectly tidy. A 2025 study of a local Holstein population found a higher frequency of the A2 allele (63 percent) than A1 (37 percent), yet measured A1 protein concentrations in milk exceeded A2 concentrations [8]. The authors suggested this could reflect more efficient expression of the A1 allele in heterozygous or A1A1 cows. Genotype at the DNA level and protein in the bulk tank are related but not interchangeable.

Historically, A1 beta-casein is described as a protein produced by a major proportion of European-origin cattle but not by purebred Asian or African cattle [6]. That geographic framing helps explain why the A1 versus A2 conversation has different weight in different dairy regions.

How Herds Are Converted to A2

Converting a herd to A2 is a genetics project, not a feed change. The steps are straightforward in principle and slow in practice.

The first step is genotyping. A DNA sample, usually from hair, blood, or ear tissue, is tested for the CSN2 variants. The result tells you whether an animal is A1A1, A1A2, or A2A2.

The second step is selection. A2A2 cows are retained as the production base. A1A1 and A1A2 cows are bred to A2A2 bulls, and their A2A2 daughters enter the milking herd while A1-carrying daughters are culled or bred out over successive generations. Bulls are genotyped too, because a single A1-carrying bull can spread the allele widely through artificial insemination.

The third step is verification. Because a herd is a population and not a single animal, milk from a converted herd is tested to confirm that A1 beta-casein is absent or below the threshold required by the buyer. Analytical methods for distinguishing A1 and A2 beta-casein at the peptide level now exist, including online trypsin digestion coupled with liquid chromatography and tandem mass spectrometry, with quantification limits in pasteurized milk reported at 0.8 micrograms per gram for A1 and 2.4 micrograms per gram for A2 [10].

The timeline is generational. A cow's genotype is fixed at conception, so a herd's A2 status improves only as new generations replace old ones. That is why A2 supply has grown gradually and why the product carries a price premium in most markets.

A1 vs A2 Milk: Side-by-Side Comparison

Feature	A1 milk (conventional)	A2 milk
Beta-casein variant	A1 and A2, ratio varies by herd	A2 only
Amino acid at position 67	Histidine	Proline
BCM-7 release during digestion	Yes, from the A1 fraction	Minimal to none from beta-casein
Lactose content	Contains lactose	Contains lactose
Protein and calorie content	Comparable	Comparable
Typical source breeds	Holstein-Friesian, Ayrshire, Red	Guernsey, Jersey, selected A2A2 Holsteins
Evidence for fewer digestive symptoms	Comparator in trials	Mixed, with positive trials in self-reported milk-intolerant people
Suitable for lactose intolerance	No	No

The table captures the central point. A2 milk is not lactose-free, low-lactose, or dairy-free. It is a protein variant swap.

What the Human Evidence Shows

The clinical literature on A2 milk is larger than most people expect and more mixed than either side of the marketing debate admits. A 2019 systematic review identified 15 randomized controlled trials, 2 case-control studies, and 8 ecological studies on A1 beta-casein and human health outcomes [11]. Most randomized trials and case-control studies looked at intermediate markers and found no significant difference between milk types, while most ecological studies reported population-level associations between A1 exposure and adverse outcomes [11]. Ecological studies cannot establish cause, and the review's authors graded the certainty of evidence accordingly.

Trials Reporting Fewer Symptoms With A2 Milk

Several randomized trials in people who self-report milk intolerance have found symptom advantages for A2 milk.

A 2016 double-blind crossover trial in 45 Han Chinese adults with self-reported lactose intolerance found that conventional milk containing both beta-casein types was associated with significantly greater post-dairy digestive discomfort symptoms, higher concentrations of inflammation-related biomarkers and BCM-7, longer gastrointestinal transit times, lower short-chain fatty acid levels, and slower cognitive response times compared with milk containing only A2 beta-casein [12].

A 2017 multicenter randomized crossover trial in 600 Chinese adults with self-reported lactose intolerance found all six gastrointestinal symptom scores were significantly lower at 1 and 3 hours after consuming A2 beta-casein milk versus conventional milk, with differences in bloating, abdominal pain, and stool measures persisting at 12 hours [5].

A 2019 randomized study in Chinese preschoolers aged 5 to 6 years with mild to moderate milk intolerance found that A2 beta-casein milk produced significantly less severe gastrointestinal symptoms, reduced stool frequency, and improved stool consistency compared with conventional milk [13].

A 2020 crossover trial in 25 lactose-intolerant subjects found lower abdominal pain scores after A2 beta-casein milk compared with conventional milk, and post hoc analysis of lactose maldigesters showed improved symptom scores and lower hydrogen production [9].

A 2020 randomized controlled trial in 40 women classified by lactose challenge found that A2 milk reduced some digestive symptoms in lactose-intolerant subjects, who experienced prolonged discomfort with conventional milk [2].

A 2024 randomized crossover trial in 40 subjects with gastrointestinal discomfort after milk found A2 milk caused less abdominal pain, fecal urgency, and borborygmus than A1/A2 milk, and fecal calprotectin decreased or rose less after A2 milk [14]. The same trial found A2 milk increased bloating and loose stools on the GSRS scale, which is a reminder that these results are not uniformly favorable.

A 2024 two-week adaptation study in 16 confirmed lactose maldigesters found fecal urgency, bloating, and flatulence were higher with A1/A2 milk than A2 milk, but day-to-day symptoms, hydrogen production, serum inflammatory markers, and antioxidant concentrations did not differ after adaptation [4]. Adaptation over two weeks did not bring A1/A2 milk tolerance up to the A2 level.

A 2025 open-label pragmatic trial in 997 healthy Australian adolescents and adults found no differences in gut microbiome composition, alpha-diversity, or function (measured in a subgroup) when participants switched from conventional to A1 protein-free milk, although women reported a marginal reduction in gastrointestinal symptoms [15].

Trials Reporting No Difference

The evidence is not one-directional.

A 2026 double-blind crossover trial in non-regular milk drinkers with self-reported cow's milk intolerance found no statistically significant between-group differences in stool frequency or consistency, overall or individual gastrointestinal symptoms, gastrointestinal transit time, or laboratory measurements including immunoglobulins, interleukin-4, and short-chain fatty acids when comparing A1 protein-free milk with conventional milk [16].

A 2023 crossover trial in 10 lactose maldigesters using magnetic resonance imaging found that gastric emptying was faster after conventional milk containing A1 and A2 beta-casein than after A2-only milk, and the authors proposed that this difference in transit may mediate lactose intolerance symptoms [3]. Faster emptying is not obviously better or worse, and the trial was small.

A 2025 randomized crossover trial in 36 self-reported milk-sensitive volunteers found no difference in perceived gut symptoms between A2 milk and hydrolyzed A1A2 milk in the lactose-tolerant group, while symptoms increased with lactose content in the lactose-intolerant group [17]. Calprotectin and high-sensitivity CRP did not rise during the trial. This study is important because it separated lactose effects from protein effects and found lactose was doing much of the work.

A 2025 crossover trial in 48 participants found overall symptoms were minimal across all milk types, with lower bloating and flatulence ratings for A2 milk compared with lactose-free A2 milk on two test days, and breath hydrogen responses that tracked lactose content rather than casein type [18]. Thirty-three participants were classified as lactose intolerant and had higher fasting and average breath hydrogen across all samples.

The Funding Question

Several of the positive trials were supported by the A2 dairy industry, and readers should weigh that when interpreting results. Many of these trials, including the Chinese adult trials [12][5] and the Purdue lactose maldigester trials [9][3][4], were funded by The a2 Milk Company, which markets A2 milk. That does not make the findings false, and several were published in peer-reviewed journals with independent co-authors. It does mean the body of positive evidence is concentrated in one funding ecosystem, which is a recognized limitation in nutrition research. The 2026 trial that found no difference [16] and the 2025 Finnish trial that found lactose was the dominant driver [17] provide useful counterweight.

A bibliometric analysis of the field concluded that based on conflicting information from primarily in vitro and animal studies and limited clinical trials with poor designs, A1 milk shows pro-inflammatory and oxidative activity, but the evidence is insufficient to associate its consumption with negative health effects, while A2 milk may be better tolerated by the digestive system of sensitive individuals [19]. That is a fair summary of where the science sits.

What About BCM-7 and Chronic Disease?

This is where the A2 conversation most often goes beyond what the evidence supports.

BCM-7 has been proposed as a factor in ischemic heart disease, type 1 diabetes, sudden infant death syndrome, autism, and schizophrenia, largely on the basis of ecological correlations and mechanistic speculation [1]. Epidemiological evidence from New Zealand has been cited as linking A1 beta-casein consumption to higher national mortality rates from ischemic heart disease, and populations consuming milk high in A2 beta-casein have been described as having lower incidence of cardiovascular disease and type 1 diabetes [1]. These are population-level observations, not causal findings.

The European Food Safety Authority reviewed the evidence in 2009 and concluded that no cause-and-effect relationship had been established between BCM-7 and noncommunicable diseases. Subsequent systematic review work has reinforced that position. The 2019 systematic review found most randomized trials and case-control studies examining intermediate markers showed no significant difference between milk types, in contrast to the ecological studies that reported population-level associations [11]. The bibliometric analysis reached a similar conclusion about insufficient evidence for negative health effects [19].

The honest position is this. BCM-7 is real, it is released from A1 beta-casein in vitro, and it binds opioid receptors. Whether dietary BCM-7 reaches meaningful systemic concentrations in humans, and whether any such exposure causes chronic disease, remains unproven. Anyone who tells you the chronic disease question is settled is going beyond the data in either direction.

A2 Milk Still Contains Lactose

This is the single most important practical point in the article, and it is frequently lost in marketing.

A2 milk contains lactose at essentially the same concentration as conventional milk. In the 2020 women's trial, the A2 milk arm was explicitly described as containing A2 beta-casein with lactose, and it was compared against a lactose-free conventional milk arm [2]. In the 2020 single-meal trial, A2 milk, Jersey milk, conventional milk, and lactose-free milk were four distinct test products, and the lactose-free product was a separate category [9]. In the 2025 crossover trial, A2 milk and lactose-free A2 milk were tested as different products, and breath hydrogen responses reflected lactose content rather than casein type [18].

Lactose malabsorption is a major cause of digestive discomfort from dairy products [2]. Lactose intolerance is caused by insufficient lactase enzyme activity in the small intestine, and the treatment is reducing lactose intake or using lactase-treated products. Switching from A1 to A2 milk does nothing for that mechanism.

The 2025 Finnish trial makes the point cleanly. When lactose-tolerant and lactose-intolerant participants were separated by genotype, there was no difference in perceived gut symptoms between A2 and hydrolyzed A1A2 milk in the lactose-tolerant group, while symptoms increased with lactose content in the lactose-intolerant group [17]. Lactose was the driver in the people who could not digest it.

If you are lactose intolerant, A2 milk is not your solution. Lactose-free milk, lactase enzyme products, or non-dairy alternatives are. If you have a diagnosed cow's milk protein allergy, A2 milk is also not your solution, because the allergenic proteins are still present. Milk protein allergy is an immune response to proteins including caseins and whey, and it requires medical management and avoidance, not a variant swap.

Practical Implications for Owners and Keepers

For most readers, the A1 versus A2 decision is a personal one rather than a medical necessity.

If you drink milk without symptoms, there is no established health reason to switch. The randomized trial evidence for benefits is concentrated in people who already report milk-related digestive discomfort, and the largest pragmatic trial in healthy adults found no microbiome differences from switching [15].

If you report mild to moderate digestive discomfort after milk, the picture is more nuanced. Some trials found symptom improvement with A2 milk in exactly that population [2][9][12][5][13], and one pilot trial found no difference [16]. If you want to test it, a reasonable approach is to keep everything else in your diet stable and change only the milk for a few weeks. If symptoms do not change, the milk variant was not your trigger.

If you are lactose intolerant, choose lactose-free products regardless of the casein type [2][18][17].

If you have a diagnosed milk protein allergy, avoid cow's milk protein entirely and follow your allergist's plan.

For producers and herd managers, the A2 decision is a market decision. Genotyping bulls and cows, breeding toward A2A2, and verifying bulk tank composition are the operational steps [8][10]. The genetics are well understood and the analytical methods exist. The question is whether the price premium justifies the multi-generation transition cost for your operation.

It helps to separate three overlapping complaints that people often bundle together: lactose malabsorption, milk protein allergy, and nonspecific post-dairy digestive discomfort. These have different mechanisms and different management. A2 milk is relevant only to the third category, and even there the evidence is mixed.

Limitations and When to Contact a Veterinarian

This article is educational and is not a substitute for veterinary diagnosis or treatment.

The A1 versus A2 literature has real limitations. Many trials are small. Several used self-reported milk intolerance rather than confirmed diagnosis. Conventional milk composition varies between studies, so "A1/A2 milk" is not a standardized exposure. A substantial share of the positive trials were industry funded. Ecological studies dominate the chronic disease literature and cannot establish causation. The 2019 systematic review found most randomized trials showed no significant difference on intermediate markers [11], and the 2026 trial found no difference in gastrointestinal physiology or symptoms [16].

Contact a physician if you or a family member experiences any of the following after consuming milk or dairy:

Blood or mucus in the stool
Persistent vomiting or inability to keep fluids down
Signs of dehydration, including reduced urination, dry mouth, or lethargy
Hives, facial swelling, wheezing, or difficulty breathing after dairy consumption, which suggest an allergic reaction and require urgent care
Weight loss, poor growth in a child, or failure to thrive
Symptoms that persist for more than two weeks despite removing the suspected trigger
Severe abdominal pain that is worsening rather than intermittent

For livestock, contact a veterinarian if a cow shows signs of mastitis, lameness, or a sudden drop in milk production, since these are management and welfare issues unrelated to beta-casein genotype but relevant to any herd transition plan.

Individual cases need individual assessment. A physician can help distinguish lactose malabsorption from milk protein allergy from functional digestive complaints, and can advise on whether a dietary trial is appropriate.

Frequently Asked Questions

What is A2 milk?

A2 milk is cow's milk in which the beta-casein protein is entirely the A2 variant, with no A1 beta-casein present [2][3]. It comes from cows that carry two copies of the A2 allele of the CSN2 gene.

What is the difference between A1 and A2 milk?

The two milks differ at amino acid position 67 of beta-casein, which is histidine in A1 and proline in A2 [1]. That single change affects how digestive enzymes cut the protein and whether BCM-7 can be released.

Does A2 milk contain lactose?

Yes. A2 milk contains lactose at essentially the same level as conventional milk, and it is not a treatment for lactose intolerance [2][9][18].

Is A2 milk better for people with lactose intolerance?

No. Lactose intolerance is caused by insufficient lactase enzyme activity, and A2 milk still contains lactose. Lactose-free milk or lactase products are the appropriate options [2][18][17].

What is beta-casomorphin-7?

BCM-7 is a seven-amino-acid peptide released when A1 beta-casein is digested. It binds mu-opioid receptors in the gastrointestinal tract and elsewhere, and it is not released from A2 beta-casein in the same way [6][1].

Do randomized trials show A2 milk reduces digestive symptoms?

Some do, particularly in people who self-report milk intolerance [2][9][12][5][13], and some do not [16]. Several of the positive trials were industry funded, so the evidence should be read with that in mind.

Has EFSA linked BCM-7 to chronic disease?

No. The European Food Safety Authority's 2009 review found no established cause-and-effect relationship between BCM-7 and noncommunicable diseases, and later systematic reviews reached similar conclusions [11][19].

How are dairy herds converted to A2?

Herds are converted by genotyping bulls and cows for CSN2 variants, breeding toward A2A2 animals, and verifying that bulk tank milk is free of A1 beta-casein [8][10]. The process takes multiple generations because a cow's genotype is fixed at conception.